Background/objective: An inflammation of the cutis and subcutis of the external auditory canal is a primary symptom in cases of acute otitis externa. It is usually treated locally, since this type of therapy ensures a high concentration of the drug and interacts at the site of inflammation with no systemic effects. This systematic review compares the efficacy of treatment using a ciprofloxacin 0.2% solution with other therapeutic options. Methods: After compiling a catalog of search terms, medical databases were searched systemati cally for randomized, controlled studies. This search initially yielded a total of 38 studies which were then evaluated by three independent reviewers. The number of studies was subsequently reduced to 14: six studies using a ciprofloxacin 0.2% solution, and eight studies using both 0.2% and 0.3% solutions.
Introduction

Otitis externa
Inflammation of the cutis and subcutis of the external auditory canal is a primary symptom in acute otitis externa. An affected pinna can be a secondary symptom. Occasionally, the eardrum can also be inflamed. 1 Inflammation of the ear can occur in an acute and a chronic form. In some cases, the clinical picture develops to a necrotizing stage. Statistically, one in ten people suffers at least once in his life from otitis externa. In 10% of cases, the inflammation is bilateral. 2 Currently, many different therapies are applied to ease the symptoms. The purpose of this review is to compare the efficacy of ciprofloxacin 0.2% antibiotic ear solution with other treatment options.
General etiology
An intact auditory canal possesses the ability to cleanse itself by migrating the sloughed epithelia cells outwards with cerumen. The main function of cerumen is to protect the membrane that lines the auditory canal against inflammation. Cerumen maintains the soft consistency of the membrane and also ensures water resistance. Whether it also submit your manuscript | www.dovepress.com
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Mösges et al has an antimicrobial effect has not yet been clarified. If the cerumen is pushed from the outer part of the auditory canal toward the eardrum using a cotton swab, its effectiveness is lowered. Should bacteria then enter the ear canal, the risk of progressive bacterial growth increases. This can occur particularly in swimming pools, which is why the term "swimmer's ear" is commonly used. 3 Likewise, congenital or acquired anatomical anomalies (eg, narrow passages), the use of hearing aids, or the aforementioned radical ear and ear canal hygiene with the complete removal of cerumen or drainage can destabilize the sensitive environment and thus predispose the external auditory canal to inflammation. 1 
Pathogens
The pH of the external auditory canal varies between 5.0 and 5.7 and is therefore slightly acidic. Such conditions inhibit bacterial growth. 1 In 1981, Brook examined the physiological, normal flora of the external auditory canal in pediatric patients. In descending order of concentration, colonization with aerobes such as Staphylococcus epidermidis, diphthe roid species, and ahemolyzing streptococci as well as anaerobes such as propionibacterium acnes, was observed. Pseudomonas aeruginosa and Staphylococcus aureus act pathogenically against such flora and are cited in the technical literature as the main causative organisms. Sporadically, viruses and fungi can also cause otitis externa. 1, 4 Clinical picture Bacterial otitis externa in its mild form can be accompanied by only minor pain and subdued swelling. In its severe form, however, the symptoms are associated with excruciating pain, otorrhea, and the complete closure of the external auditory canal. The result is conductive deafness. 1 Apart from the typical acute form of otitis externa, special forms can appear such as otitis externa circumscripta, which emanates from a hair follicle inflammation, or otitis externa necroticans ("maligna"), which can take a fulminant course and therefore requires maximum, usually intravenous treatment. 1, 5 In the majority of published clinical studies on the treatment of otitis externa, pain, swelling, otorrhea, and redness are evaluated as typical parameters for rating the clinical signs.
Therapy
Otitis externa is usually treated locally. 1 Ototoxic antibiotics such as aminoglycosides should not be applied in patients with a perforated tympanic membrane. If an antibiogram has been made, the optimum antibiotic otologic drug can be determined. If none is available, "calculated antibiosis" is recommended, ie, a drug is used that is effective against the two most common pathogens S. aureus and P. aeruginosa. 6 Individual decisions must be made in case of resistance. Often, an antiseptic ingredient such as aluminium acetate/ acetic acid is added to the antibiotic. Due to their acidic properties, these substances are especially suitable for lowering the pH value in the auditory canal, so that the main pathogens P. aeruginosa and S. aureus, which reach their optimal pH between 6.5 and 7.3, do not obtain perfect growing conditions or, in an ideal case, are killed. 1, 7 For years, glucosteroids had the reputation of primarily reducing the swelling of the auditory canal. Newer studies, however, also ascribe to them antibacterial and antifungal effects in otitis externa. Yet the number of available studies on steroidal monotherapies is still rather low. 5 Nonsteroidal antiinflammatory drugs should also be administered for pain relief. 1 
Ciprofloxacin
Ciprofloxacin is a synthetic antibiotic with a broad spectrum of activity and has the chemical formula C 17 H 18 FN 3 O 3 .
Belonging to the group of fluoroquinolones (gyrase inhibitors), it acts as a bactericide particularly against gramnegative pathogens by inhibiting DNA replication (topoisomerase II) and interfering in the enzymatic activity of topoisomerase IV, both of which are required for the bacteria's cell division, transcription, repair, and recombination. It is moderately effective against gram positive pathogens, while it shows no relevant activity against fungi or parasites. 8 In 75% of cases, ciprofloxacin is eliminated unchanged by renal excretion. It is also metabolized through the liver and eliminated through bile and is thus subject to enterohepatic circulation. 8 Ciprofloxacin ranks among the most effective fluoroquinolones against P. aeruginosa and can also show very high in vitro activity against enterobacteria and Haemophilus influenzae. Being the only antibiotic available for oral treatment of infections caused by P. aeruginosa, it is administered in particular to treat chronic purulent otitis media, and can be applied locally and systemically to treat acute otitis externa. 9 Ciprofloxacin constitutes the drug of choice for treating severe otitis externa in children and adolescents as it has been the subject of extensive investigation and is available in syrup form.
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Acute otitis externa and ciprofloxacin otic Besides its systemic effect, ciprofloxacin is used more often topically for its local effects in the form of eye or ear drops. This fluoroquinolone thereby possesses a very broad spectrum of indications which range from complicated uri nary tract infections, infections of the respiratory system, skin and bones, to severe typhoid salmonella infections, or bacterial conjunctivitis. Known side effects include gastro intestinal complaints (nausea, diarrhea, dyspepsia), disorders of the central nervous system (headache, nervousness/rest lessness, dizziness, tremor, hyposmia), and skin irritations and eosinophilia. 11 The undesirable effects of systemic treatment can be largely avoided through topical administration, however. A high local concentration is in fact attained, yet resorption does not occur. Therefore, itching or burning at the applica tion site or superinfections of the ear can arise due to robust pathogens. Allergic reactions occur very rarely. 10 Systemic side effects of local application occasionally include dizzi ness and headache. Restrictions with respect to language, publication date, or publication status were not initially made. This review was also limited to published work. The last search was started on 1 March 2011.
Materials and methods
Search methods used to identify studies
Patients
Patients (both children and adults) with the diagnosis of acute otitis externa were included in the review. Not included were patients who suffered from a chronic form of external otitis or otitis media.
Parameters
Symptom improvement and microbiological eradication were defined as primary outcome parameters. Time to com plete disappearance of symptoms and any side effects were observed as further aspects.
Results
Search results
Thirtyeight studies satisfied our search criteria, and we examined the abstracts of these. When this process was completed, the number of suitable studies decreased to 36; we then worked through their full texts ( Figure 1 ). After three reviewers came to a consensus concerning further elimina tions, six and eight studies, respectively, were available for this systematic review (Table 1) . [12] [13] [14] [15] [16] [17] [18] [19] We were denied access to the full text of two of these eight randomized controlled trials. The comprehensive publication by Lildholdt et al 15 and the text by Psifidis et al 18 could not be requested, which is why detailed data are missing.
Unpublished studies were not considered in this systematic review.
Background (included studies) Treatment doses
Besides six studies that investigated a 0.2% ciprofloxacin drug, we also included two more studies that used a 0.3% ciprofloxacin product (Table 2 ). 14, 16 The ciprofloxacin dose of the ear solutions used in the individual studies was comparable. The majority planned a 7day application phase, during which the study participants applied three drops to each ear twice daily. Marom et al 16 raised the dose to four drops (0.3% ciprofloxacin), and Goldenberg et al 14 doubled the application period to 2 weeks. The exact dose remains unclear in the study by Drehobl et al 13 in which the study period was also 7 days, with applications twice daily, but the study specified the dose as ampoule ("vial") rather than stating the number of drops.
Outcomes assessed Clinical response
Clinical success was, in part, classified differently and measured at various points in times (Table 2 ). In addition, the definition of treatment success varied slightly among the studies. Some studies defined clinical success as complete recovery (resolution) with complete freedom from symptoms. In others, it included mild symptoms, but a distinct improvement from the initial value. In principle, the symptoms and signs typical for the disease and used in the evaluation were similar. They included edemas, pain, or hypersensitivity of the ear, and otorrhea. An alternative approach to analyzing pain was chosen by Marom et al 16 who, instead of the time to end of pain, evaluated the basic development of pain perception based on daily entries via the visual analog scale.
Time to recovery -time to end of pain
Microbiological response
With the exception of one study, the microbiological effectiveness of the study medication, among others, was measured as the secondary outcome measure. 16 Upon inclusion of the patients, samples were taken to determine the causative organisms. This procedure was repeated at the end of treatment (or alternatively after a followup period). The classification scheme was defined differently in the individual studies:
Drehobl et al 13 divided the samples into "no exudates observed", "exudate was present, but there was no growth on culture", "exudate was present, and culture showed some patho gen growth at baseline or patient's response was clinical failure", or "exudate was present, and culture showed one or more new pathogens" and assessed them at the end of treatment and also after a followup period. Patients who tested positive for bacteria at the beginning of the study and then tested negative later during the study came into the category "microbial cure." 
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Acute otitis externa and ciprofloxacin otic Arnes et al 12 Pistorius et al 17 , and Psifidis et al 18 defined outcome critaria from "eradication" to "superinfection" or "reinfection" and examined the microbiological activity at the end of treatment and after followup. The change or the reduction of pathogenic infections could be determined in this way for each group and each pathogen.
In contrast, Lildholdt et al 15 in their study evaluated the number of persisting cultures after the end of treatment, which was also relevant for Goldenberg et al 14 that is, whether and to what extent bacterial proliferation still existed after therapy was completed.
Adverse events
In the majority of the studies, adverse events were evaluated as an expression of safety. Four studies specified such events additionally 13, 16, 17, 19 by explicitly analyzing medication related adverse events; three studies evaluated clinical side effects/adverse events in general. 12, 14, 18 Whether adverse events were of relevance in the study by Lildholdt et al remains unclear.
Timing of outcome assessment
The relevant point in time at which the primary and second ary outcome measures were assessed differed among the studies. Whereas in some studies the data were included in the analysis directly after the application phase was completed, others defined the time after a followup phase as decisive for the analysis. In only one case, the data from Day 3-4 formed the basis of the analysis. 14 In the studies that conducted an analysis with data directly after treatment had ended, the point in time varied between Day 8 and Day 17. In the studies that collected data relevant to the target value after a followup phase, the time span ranged from Day 15 to Day 35.
Study results
Clinical cure
The included studies demonstrate the statistical equivalence between ciprofloxacin (0.2%) and the reference product PNH (Table 3) . Some studies investigated the cure rate after completion of treatment. 12, 17, 19 Here, the rate for patients whose condition fell into the category "clinical resolution" or "improvement" ranged between 93% and 100%. Studies that evaluated the outcome parameters after a followup period showed cure or improvement rates between 86.6% and 96.7%. 13, 15, 18 Consequently, comparably high success rates for the ciprofloxacin 0.2% drug were determined in these studies.
Similar results were ascertained in the studies that inves tigated a higher concentration of ciprofloxacin (0.3%). 14, 16 In 
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Risk of bias
The greatest susceptibility to systematic distortions of the study results constituted the insufficient blinding of the included studies. While two study groups explicitly men tioned using nonblinding, 16, 18 four other authors made no comment whatsoever in this regard. 12, 14, 15, 18 Based on the fact that blinding was not addressed, however, it is to be assumed that blinding did not occur and the studies were openlabel. In the study by Drehobl et al 13 the evaluator at least was blinded, and only Roland et al 19 conducted an observer/investigator blinded study.
In addition, the randomization procedure remained unclear in a large proportion of the studies. Although all were randomized, controlled studies according to the pub lications, the randomization process was mentioned in only three studies. 12, 16, 19 Another deficit with reference to the included studies was the absence of two full texts. We could only draw on the information from the abstracts by Lildholdt et al 15 and Psifidis et al 18 because we were denied access to the complete, comprehensive material.
Discussion
The outcome measure "clinical success" consistently shows higher success rates in patients treated with the fluoro quinolone, than in the control groups. At the same time, the authors point out -in addition to the effectiveness of the active ingredient -the absence of any ototoxicity and the low systemic exposure caused by ciprofloxacin.
In summary, clinical equivalence can be determined for both of the treatment possibilities ciprofloxacin/ hydrocortisone and PNH plus amoxicillin in adults and children. However, low systemic exposure, the absence of ototoxicity, and the smaller dose speak clearly for treatment with ciprofloxacin.
Ciprofloxacin stands out due to its low rate of side effects. Adequate safety is thereby given with this fluoroquinolone.
For this reason, ciprofloxacin is not only noninferior to other classes of antibiotics but also to antibiotic drugs that are combined with glucocorticoids.
Studies that evaluated microbiological activity come to the conclusion that the organism P. aeruginosa represents the main pathogen in the investigated population having acute otitis externa. The authors consistently ascertained high in vitro activity of ciprofloxacin against P. aeruginosa.
Special attention must be paid to patient compliance in the included studies. The lower the required application rate of the otologic drug, the more probable it is that the patients adhere to therapy and apply the medicine regularly. Thus we can conclude that patients requiring fewer daily drug administrations will comply more closely with the treatment plan.
When considering the bias, and consequently the results, we should pay particular attention to a certain distortion: due to the different daily application rates of the otologic drugs used, doubleblinding of the study could not always be achieved.
The possibility of including a much larger number of clinical studies in this review would have existed if the question at hand had also applied to ciprofloxacin 0.3% solution.
Other studies not included in this review combined cipro floxacin 0.2% solution with the glucosteroid dexamethasone, which can be categorized as a glucocorticoid belonging to the active substance class two to three analogous to the clas sification of therapeutic index of topical dermatotherapy, and is thus to be considered potent. 20 These combination drugs were in turn tested against "conventional" combination drugs such as PNH. The efficacy of ciprofloxacin could be therefore increased.
Conclusion
The studies included in this review demonstrate the statistical equivalence of ciprofloxacin (0.2%) and the reference product PNH, and thereby confirm the hypothesis of noninferiority in terms of the cure rate and microbiological eradication. The efficacy of ciprofloxacin 0.2% antibiotic ear solution can be acknowledged.
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